This study demonstrated that ALCs or CD8+ T-cell counts measured 1 month after chemoradiotherapy can serve as effective prognostic predictors in NSCLC patients receiving chemoradiotherapy followed by consolidation immunotherapy. Here, CD8A is linked to non-small cell lung carcinoma.